A GrowFlow perspective on the federal policy shift now reshaping the industry
For the legal cannabis industry, the central contradiction has been simple. Cannabis has been legal in most states, but the federal government has treated it the same way it treated heroin. That gap has defined how operators raise capital, how they bank, how they pay taxes, and how they plan for growth.
That gap is finally beginning to close. Medical cannabis has been rescheduled from Schedule I to Schedule III under the Controlled Substances Act, and the rollout is now underway. It is the most significant federal policy shift the legal cannabis industry has ever seen.
It is also one of the most misunderstood. There is meaningful confusion across operators and industry coverage, and the distinction matters: this is a medical reclassification. It is not full federal legalization, and it does not, on its own, extend to the adult-use market. Operators who blur the two will misallocate capital and miss the actual opportunity in front of them.
What follows is a clear-eyed walk through what changed, what did not, and what cannabis operators, GrowFlow customers and the broader market, should be doing about it.
Schedule I, by statutory definition, is reserved for substances with no accepted medical use, a high potential for abuse, and no accepted safety under medical supervision. Schedule III is for substances with accepted medical use and a moderate-to-low potential for dependence. The move from I to III is not a downgrade in regulation. It is the federal government formally acknowledging that cannabis has medical value.
That distinction is the entire story. The DEA did not legalize cannabis. Congress did not pass a comprehensive cannabis bill. The federal government recognized cannabis as a medicine. Everything, from tax implications to research implications to banking conversations, flows from that single fact.
Medical cannabis, including FDA-approved drug products containing marijuana, and medicinal marijuana products subject to a qualifying state-issued license, are now regulated under Schedule III. Adult-use cannabis is not. State-licensed recreational dispensaries remain federally restricted in much the way they were before rescheduling.
For medical operators, the changes are real and material.
The most immediate impact is on Section 280E of the Internal Revenue Code, which prohibits businesses trafficking in Schedule I or II substances from deducting ordinary business expenses. 280E has been the single largest financial weight on this industry. It is why a dispensary with a healthy pre-tax margin in any other sector can end up with an effective tax rate north of 70 percent. With cannabis on Schedule III, medical operators are no longer captured by 280E. Payroll, rent, marketing, software, employee benefits, the entire normal cost of doing business, becomes deductible again.
That is not a marginal improvement. For most medical operators GrowFlow works with, the difference between operating under 280E and operating without it is the difference between treading water and being able to reinvest in the business.
The second material change is research. Schedule I status made cannabis research effectively impossible at most American universities and pharmaceutical companies. Schedule III status opens the door to legitimate clinical trials, FDA-aligned product development, and the opportunity to establish a real evidence base for the medical claims this industry has been making for years. Over time, that benefits everyone, especially patients.
The third is capital. Institutional investors who have stayed out of cannabis on policy grounds now have a federal framework they can underwrite against, at least for medical operators. Banking conversations that used to end at “Schedule I” can now move forward.
Adult-use cannabis was not, by itself, addressed in the move to Schedule III. State-licensed adult-use dispensaries continue to operate in a federal environment that has not yet caught up with their business model. 280E remains an issue for adult-use operations, and the federal banking picture has not materially changed on the basis of rescheduling alone.
That said, the picture is not static. Several adjacent federal efforts are advancing in parallel and warrant close attention:
The SAFE Banking Act, which would let federally chartered banks serve state-legal cannabis businesses regardless of medical or adult-use designation, has continued to build bipartisan momentum across recent sessions of Congress.
Federal proposals contemplating a broader review of how adult-use cannabis is treated under the Controlled Substances Act have moved into active discussion, with regulators signaling a willingness to revisit the topic now that medical rescheduling has been completed.
State-level adult-use expansion has continued, broadening the political constituency for federal reform and narrowing the gap between state practice and federal law.
None of this is guaranteed, and timelines remain uncertain. But the directional read is that adult-use reform is increasingly a question of when and in what form, rather than whether. Medical rescheduling cleared a significant political and regulatory hurdle. The remaining work is harder, but it is on the federal agenda in a way it has not been before.
In the meantime, adult-use operators should plan around the policy that exists today: federal restrictions remain, 280E continues to apply, and federal banking access remains limited. The opportunity for adult-use businesses lies in using this interim period to build the kind of operational foundation that will translate cleanly into a more favorable federal environment when it arrives.
For businesses serving both medical and adult-use markets under one roof… they should expect their accounting to get more nuanced, not less. The medical side of the business may now qualify for ordinary business deductions; the adult-use side does not. Clean separation between the two has become a meaningful financial and compliance discipline, and one that pays off in both directions: tax savings now on the medical side, and a cleaner operational base for whatever comes next on the adult-use side.
A few things rescheduling did not, and will not, do on its own. It did not create an interstate cannabis market. It did not eliminate state licensing requirements. It did not preempt state cannabis laws. It did not federalize testing standards. It did not legalize home cultivation. It did not change METRC or any other state traceability requirement. It did not change how the DEA treats unlicensed cannabis.
Compliance remains the central operational discipline of this business, and it will remain so as federal reform continues to unfold.
The operators who win the next phase of this industry will not necessarily be the largest. They will be the most operationally prepared. Rescheduling sharpens that point rather than softens it.
Medical operations and mixed operations should treat this year as the moment to get their books in shape. The tax savings from exiting 280E on the medical side are real, but only if records can substantiate them. If accounting cannot cleanly separate medical from adult-use revenue, costs, inventory, and labor, those savings cannot be fully captured. GrowFlow has been working closely with operators on exactly this challenge.
Adult-use operations should treat this year as the moment to build the operational fundamentals (inventory accuracy, margin discipline, scalable systems) that will let them compete as federal reform extends further. When that shift comes, capital will flow toward the cleanest operators first.
Mixed operators face both tasks at once, with the added priority of getting the medical and adult-use separation question in order before it becomes a tax-season scramble.
Rescheduling is the most significant federal acknowledgment cannabis has ever received. It is also, at this moment, a targeted one. The medical industry now operates under a federal framework. The adult-use industry is on a separate trajectory that is moving, but moving more deliberately.
Both segments will keep evolving. Both deserve clarity about where they stand today. And both will be best served by operators who plan around the policy that exists now while preparing operationally for the policy that is coming.